ArticleAmerican journal of translational research2024
Effect of intraoperative dexmedetomidine on heart-type fatty acid binding protein, CK-MB, and cardiac troponin I levels, and postoperative delirium in patients with heart valve replacement.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis retrospective study aimed to evaluate the impact of intraoperative dexmedetomidine on myocardial injury markers (heart-type fatty acid binding protein [H-FABP], creatine kinase-mb [CK-MB], and cardiac troponin I [cTnI]) and postoperative delirium in patients undergoing heart valve replacement.
methodsClinical data from 160 cardiac patients who underwent heart valve replacement with cardiopulmonary bypass (CPB) between January 2019 and January 2024 were analyzed. Patients were divided into an observation group (n = 82) receiving dexmedetomidine and a control group (n = 78) without dexmedetomidine. After propensity score matching, both groups comprised 53 patients each. Outcome measures included myocardial injury markers, postoperative delirium incidence, and perioperative parameters.
resultsThe observation group showed shorter postoperative recovery durations, reduced intraoperative sufentanil requirements, and lower myocardial injury markers 1 day postoperatively (all P < 0.001). No significant differences were found in midazolam dosages (all P > 0.05), while propofol and sufentanil dosages were lower in the observation group (both P < 0.001). The incidence of postoperative delirium was significantly lower in the observation group (P = 0.014), with cardioversion time and propofol dosage identified as delirium risk factors.
conclusionDexmedetomidine use during heart valve replacement surgery was associated with improved postoperative outcome, including reduced myocardial injury and lower postoperative delirium incidence. These findings suggest a potential role for dexmedetomidine in enhancing patient recovery, although further research is needed to explain its impact on postoperative delirium.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.